Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight

The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.

11/10/2026, 1:00 PM • GlobeNewswire

Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth

The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.

11/10/2026, 11:00 AM • GlobeNewswire

Novartis ranks first place in 2026 Access to Medicine Index

Novartis ranked first place in the 2026 Access to Medicine Index for the second consecutive time, scoring 3.86 out of 5 and becoming the only company to achieve top rankings across all technical areas since the index began in 2008. The company reached 304 million patients in 2025 and has expanded programs for cancer, heart disease, and malaria treatments, including launching Coartem® Baby and advancing next-generation antimalarial KLU156.

11/10/2026, 8:00 AM • GlobeNewswire

Trogenix appoints industry veterans John Young as Chair and Josh Murray as Non-Executive Director to support global strategy, commercial foundation and patient access

Trogenix Ltd, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its next phase of growth. Young brings 35+ years of pharmaceutical leadership experience from Pfizer, while Murray brings capital markets expertise from Goldman Sachs and Orca Bio. The appointments follow breakthrough pre-clinical data published in Nature and the dosing of the first patient in the Phase I/II ADePT trial for glioblastoma.

11/10/2026, 2:00 AM • GlobeNewswire

Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, showing significant NEK7 degradation and reduction in cardiovascular disease markers with safety comparable to placebo. The company plans to initiate three Phase 2 studies in gout, coronary artery disease, and hidradenitis suppurativa. Additionally, Novartis initiated Phase 2 studies of partnered program MRT-6160 in Sjögren's disease and psoriatic arthritis, triggering $87.5 million in milestone payments. The company maintains a strong cash position of $582.6 million, expected to support operations into 2029.

11/05/2026, 7:00 AM • GlobeNewswire

Novartis: 3 Key Takeaways for Long-Term Investors

Novartis raised its full-year 2026 core operating income guidance to in-line to low-single-digit growth after delivering 4% net sales growth in Q3 2026. The company is successfully offsetting patent expirations through sales of newly launched priority medicines, with Rhapsido peak sales guidance upgraded to over $4 billion. Operating margins are on track to reach 40% by 2029 as SG&A expenses fell 7% while maintaining top-line growth.

11/03/2026, 8:27 PM • The Motley Fool

BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight

The BTK inhibitors market is expected to experience steady growth through 2036, driven by increasing prevalence of B-cell malignancies, established clinical benefits, and an expanding pipeline of next-generation therapies. Key developments include FDA approvals for new indications and multiple drugs in clinical trials targeting oncology and autoimmune diseases across the 7MM markets.

11/02/2026, 1:00 PM • GlobeNewswire

Should You Buy Royalty Pharma Stock Before Nov. 4?

Royalty Pharma shares have rallied toward 52-week highs ahead of Q3 2026 earnings on Nov. 4, but investors should focus on long-term prospects rather than short-term earnings catalysts. Analysts expect 8.7% sales growth and flat earnings, with potential upside from positive pipeline updates on cancer treatments and other drug candidates, though negative news on pelacarsen could weigh on the stock.

10/29/2026, 9:30 AM • The Motley Fool

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

10/28/2026, 1:00 PM • GlobeNewswire

Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer

Matchpoint Therapeutics appointed John O'Malley, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its pipeline of first-in-class oral small molecules for autoimmune and inflammatory diseases. The appointment follows the company's recent $150M Series B financing. Dr. O'Malley brings extensive immunology expertise from previous roles at CRISPR Therapeutics and Sanofi.

10/14/2026, 7:00 AM • GlobeNewswire

Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026

Novartis will present Phase III REMODEL-1/-2 trial results for remibrutinib, an oral BTK inhibitor for relapsing multiple sclerosis, at MSToronto2026. The company will also showcase expanded evidence for Kesimpta (ofatumumab) across multiple studies including pediatric MS, treatment-naive patients, and pregnancy/breastfeeding outcomes. An investor call will follow the remibrutinib data presentation.

10/07/2026, 7:00 AM • GlobeNewswire

Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026

Sironax, a clinical-stage biotechnology company, has been recognized by Fierce Biotech as one of the 15 most innovative and promising private biotech companies of 2026. The company is advancing clinical-stage programs including SIR2501 (SARM1 inhibitor), SIR4156 (NAMPT activator), and SIR9900 (RIPK1 inhibitor) for neurodegenerative, metabolic, inflammatory, and immunological diseases. Sironax recently acquired a brain delivery platform to address blood-brain barrier challenges.

10/05/2026, 11:00 AM • GlobeNewswire

Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity

Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.

10/02/2026, 4:55 AM • GlobeNewswire

Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights

Following trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption.

10/01/2026, 1:53 PM • GlobeNewswire

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.

10/01/2026, 12:30 PM • The Motley Fool